Author Archives: admin

HYPO-RT-PC phase 3 trial

Congratulations to all the 12 Swedish and Danish centers that have contributed to the HYPO-RT-PC phase 3 trial! As the first published randomised trial on ultra-hypofractionated radiotherapy for prostate cancer, Lancet 18 2019, this groundbreaking study with 1,200 patients will lead to an increased use of ultra-hypofractionation. Fiducial markers will thereby become even more important. We […]

New study confirms low risk and great marker stability

We are happy to share this new study about Gold Anchor from the Karolinska University Hospital in Stockholm, Sweden, with you. In 621 consecutive prostate cancer patients, the frequency of urinary tract infections (UTI) and marker loss was evaluated after transrectal implantation of three Gold Anchor ™ (GA) fiducial markers using thin 22 gauge needles. […]